What features do you consider when you want to design an anti-cancer MHC class I peptide vaccine?
You want to design a vaccine that reacts against the host's MHC? Or a vaccine that reacts against the cancer epitope that binds MHC?
I want to design a vaccine that reacts against the cancer epitope that binds to MHC class I
Oh. You want to boost the host Class I (MHC/HLA) response to the cancer.
Some people do that by growing up stem cells ex vivo, transfecting them with a Tcell receptor that is engineered to bind the cancer.
You want to do it with a vaccine. I like vaccines, because they're highly cost-effective for public health. You probably will want to identify a neo-antigen in the cancer. You want to avoid a common "self" antigen, because it will be difficult to raise a response, and it may cross-react with healthy tissue. Many cancers express defective tumor suppression genes.
thanks for your response. yes I want to do that and what you recommend to me based on your knowledge and experiences?
As I wrote before, void using a common "self" antigen, because it will be difficult to raise a strong response, and if you do so it may cross-react with healthy tissue.
Many cancers express defective tumor suppression genes. Some of these are gene fusions that code for neoantigens. Those are good choices. Some are common, but most are tumor-specific. In mice you can experiment with various adjuvants.
thanks for your response. fortunately I have considered these items. what is your opinion about considering molecular weight and pI of peptides or interleukins secretion?
MW. The paradigm is that MHC I receptors usually bind linear epitopes 8-11 amino acids long. So you don't need to worry about reproducing discontinuous epitopes via native-like folding, as we do for Class II. Computational tools are available for epitope prediction, but they are not perfect. I found that 20mer peptides are a good practical size.
pI. Peptides that dissolve easily in aqueous buffer near pH 7 are easiest to work with in the lab. But I found conjugates that precipitate are still effective as immunogens.
IL secretion. I do not understand that part of your question.
- Badges
- Science topic